Interactive Features

Test Your Knowledge

Quiz: Which Approach Offers Improved Safety with J591 for mCRPC?

07/29/2021

Which treatment approach demonstrates greater safety outcomes when using a full-length antibody to target PSMA, particularly with actinium J591, for patients with mCRPC?

Which treatment approach...

07/29/2021

Oncology

Test Your Knowledge

Quiz: Which Therapy Provides Targeted Radiation Delivery for PSMA-Expressive mCRPC?

07/29/2021

Which type of therapy for PSMA-expressive mCRPC supports targeted radiation delivery to tumors and prevents excessive damage to normal tissue?

Which type of therapy for...

07/29/2021

Oncology

Test Your Knowledge

Quiz: Somatic Sequencing in Metastatic Prostate Cancer

07/28/2021

True or False: Somatic sequencing of metastatic tissue in prostate cancer is challenging due to the bone‑trophic nature of advanced prostate cancer, as well as the diagnostic yield from sequencing bone metastases being quite low.

True or False: Somatic...

07/28/2021

Oncology

Test Your Knowledge

Quiz: What Data Led to the Rucaparib Approval for BRCAmut+ mCRPC Treatment?

06/01/2021

True or False: Rucaparib was approved for treatment of BRCAmut+ mCRPC based on response rate and patient response duration.

True or False: Rucaparib was...

06/01/2021

Oncology

Test Your Knowledge

Quiz: Rucaparib Treatment in BRCAmut+ mCRPC

06/01/2021

True or False: 10% of men were taken off rucaparib treatment entirely by their doctors due to side effects; however, the reason was different for each patient.

True or False: 10% of men were...

06/01/2021

Oncology

Test Your Knowledge

Quiz: Can You Identify the Two Types of BRCA Gene Mutations?

06/01/2021

What are the two types of BRCA gene mutations?

What are the two types of BRCA...

06/01/2021

Oncology

Test Your Knowledge

Quiz: The Role of BRCA Status in Prostate Cancer Treatment

06/01/2021

True or False: BRCA gene mutations increase the likelihood of developing certain cancers, including prostate cancer, and may help your doctor anticipate the aggressiveness of your disease and evaluate treatment options.

True or False: BRCA gene...

06/01/2021

Oncology

Test Your Knowledge

Quiz: Does Adding Hormone Therapy Extend Survival in Prostate Cancer?

06/27/2019

True or false: Salvage radiotherapy combined with short-term hormone therapy significantly improved metastatic-free survival compared with salvage radiotherapy alone in patients who underwent prostatectomies.

True or false: Salvage...

06/27/2019

Oncology

Test Your Knowledge

Quiz: Does Carbon Ion Radiotherapy Reduce Subsequent Primary Cancer Risk in Prostate Cancer?

04/10/2019

True or false: Carbon ion radiotherapy has been shown to reduce the risk for subsequent primary cancers in patients with localized prostate cancer.

True or false: Carbon ion...

04/10/2019

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology